AKTS

AKTIS ONCOLOGY INC

• Dow Jones·03/31 11:04

  Aktis Oncology Price Target Raised to $33.00/Share From $30.00 by HC Wainwright & Co.

• Dow Jones·03/31 11:04

  Aktis Oncology Is Maintained at Buy by HC Wainwright & Co.

• TipRanks·03/31 10:55

  Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target

• Benzinga·03/31 10:55

  HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $33

• TipRanks·03/31 10:31

  Aktis Oncology price target raised to $33 from $30 at H.C. Wainwright

• Reuters·03/31 10:18

  AKTIS ONCOLOGY, INC. <AKTS.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $33 FROM $30

• Reuters·03/31 07:39

  U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks

• TipRanks·03/30 23:40

  Analysts Conflicted on These Healthcare Names: Aktis Oncology, Inc. (AKTS) and Ramsay Health Care (OtherRMSYF)

• Dow Jones·03/30 20:45

  Aktis Oncology Gets FDA Clearance for Phase 1B Trial of Tumor Treatment

• TipRanks·03/30 20:17

  Aktis Oncology announces FDA clearance of AKY-25191 trial

• Seeking Alpha·03/30 20:09

  Aktis Oncology, Inc. reports FY results

• Reuters·03/30 20:05

  Aktis Oncology FY25 net loss widens to $64M; R&D expenses climb to $68M

• Dow Jones·03/30 20:01

  Press Release: Aktis Oncology Announces FDA -2-

• Dow Jones·03/30 20:01

  Press Release: Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

• TipRanks·03/09 12:25

  3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts